Welcome to our dedicated page for Xtant Medical SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xtant Medical Holdings, Inc. filings document a medical technology issuer with orthobiologics, spinal implant systems, and related surgical-product commercialization. Recent Form 8-K reports disclose operating and financial results, non-GAAP adjusted EBITDA measures, material agreements, and Regulation FD communications tied to product distribution and portfolio transactions.
The company's SEC record also covers completed dispositions of Coflex and CoFix assets and Paradigm Spine GmbH, related promissory-note repayment and term-loan prepayment, and proxy governance matters. Definitive proxy and annual-meeting filings document director elections, stockholder votes, common-stock voting mechanics, and amendments to the Xtant Medical Holdings, Inc. 2023 Equity Incentive Plan.
Xtant Medical Holdings, Inc. director Tyler Lipschultz filed an initial insider ownership report on Form 3. The filing states that, as of the event date of August 1, 2025, no securities of Xtant Medical Holdings, Inc. are beneficially owned.
Xtant Medical Holdings, Inc. established November 7, 2025 as the date for its 2025 Annual Meeting of Stockholders and said it anticipates printing the proxy statement on or about September 12, 2025 and mailing or making it available commencing on or about September 15, 2025. The company noted the meeting date changed by more than 30 days from last year.
Because of that change, stockholder proposals under Rule 14a-8 must be received at the company’s principal executive offices by the close of business on August 18, 2025. Other stockholder proposals and director nominations under the Bylaws also must be delivered in writing to the Corporate Secretary by August 18, 2025. Stockholders seeking to solicit proxies for alternative director nominees must comply with the universal proxy requirements, including providing written notice no later than September 8, 2025.
Abhinav Jain filed an SEC Form 3 reporting his initial statement of beneficial ownership for Xtant Medical Holdings, Inc. (XTNT) related to an 08/01/2025 event. The filing identifies Mr. Jain as a Director and provides his address. The form explicitly states No securities are beneficially owned by the reporting person. The document is signed by an attorney-in-fact on 08/08/2025.